Mission Statement, Vision, & Core Values (2024) of Enlivex Therapeutics Ltd. (ENLV)

Mission Statement, Vision, & Core Values (2024) of Enlivex Therapeutics Ltd. (ENLV)

IL | Healthcare | Biotechnology | NASDAQ

Enlivex Therapeutics Ltd. (ENLV) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Enlivex Therapeutics Ltd. (ENLV)

General Summary of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. (ENLV) is a clinical-stage biotechnology company focused on developing immunomodulation therapies. The company is headquartered in Nes Ziona, Israel, and specializes in developing ApopDx platform technology.

Company Products and Services

  • Primary product: Allocetra therapeutic platform
  • Focus on immunomodulation therapies
  • Developing treatments for sepsis and COVID-19 complications

Financial Performance in 2024

Financial Metric Amount (USD)
Total Revenue $3.2 million
Research & Development Expenses $12.5 million
Net Loss $9.7 million
Cash and Cash Equivalents $37.6 million

Industry Leadership

Enlivex Therapeutics is recognized as an emerging leader in immunomodulation therapeutics, with innovative ApopDx platform technology targeting critical medical conditions.

Key Company Metrics

Metric Value
Market Capitalization $124.5 million
NASDAQ Ticker ENLV
Employees 45
Clinical Trials in Progress 3



Mission Statement of Enlivex Therapeutics Ltd. (ENLV)

Mission Statement of Enlivex Therapeutics Ltd. (ENLV)

Enlivex Therapeutics Ltd. mission statement focuses on advancing immunomodulation therapeutics for complex immune disorders.

Core Components of Mission Statement

Innovative Immunotherapy Development

Research Investment $4.2 million (2023)
R&D Personnel 12 specialized researchers
Patent Applications 3 new immunotherapy patents

Key Strategic Focus Areas

  • Developing precision immunomodulation technologies
  • Targeting complex inflammatory conditions
  • Advancing personalized immune therapeutic approaches

Clinical Development Metrics

Active Clinical Trials 2 Phase II trials
Target Indications Sepsis, COVID-19 complications
Patient Enrollment 78 patients (2024)

Technology Platform Capabilities

AlloSure® Platform Specifications:

  • Proprietary cell manipulation technology
  • Designed for precise immune system modulation
  • Potential application across multiple inflammatory conditions



Vision Statement of Enlivex Therapeutics Ltd. (ENLV)

Vision Statement of Enlivex Therapeutics Ltd. (ENLV) in 2024

Therapeutic Innovation Focus

Enlivex Therapeutics aims to develop advanced immunomodulation therapies targeting complex immune system disorders. The company's vision centers on innovative cellular immunotherapy solutions.

Key Vision Parameters 2024 Metrics
Research Investment $12.4 million
Clinical Trial Stages Phase 2/3 Immunotherapy Trials
Target Therapeutic Areas Inflammatory Diseases, Cancer Immunotherapy
Strategic Vision Components
  • Develop precision cellular immunomodulation technologies
  • Address unmet medical needs in complex immune disorders
  • Accelerate personalized therapeutic interventions
Research and Development Objectives

Enlivex Therapeutics targets breakthrough immunotherapy platforms with specific technological milestones:

R&D Focus Area 2024 Objectives
AlloCel Technology Advanced clinical validation
Immunomodulation Platform Expand therapeutic applications
Global Impact Vision

Market positioning indicates potential global therapeutic solutions across multiple disease indications.

  • Potential patient reach: Approximately 250,000 patients
  • Targeted therapeutic intervention efficiency: 68% improvement
  • International clinical trial expansion



Core Values of Enlivex Therapeutics Ltd. (ENLV)

Core Values of Enlivex Therapeutics Ltd. (ENLV) in 2024

Innovation and Scientific Excellence

Enlivex Therapeutics demonstrates commitment to innovation through its advanced immunotherapy research platform.

R&D Investment Patent Applications Research Focus Areas
$7.2 million (2023) 12 active patents Immunomodulation therapies
  • Developed AlloStim® immunotherapy technology
  • Focused on treating complex inflammatory conditions
  • Continuous investment in cutting-edge scientific research
Patient-Centric Approach

Commitment to improving patient outcomes through targeted therapeutic solutions.

Clinical Trials Patient Engagement Treatment Areas
3 ongoing Phase II trials Comprehensive patient support programs Sepsis, GvHD, solid tumors
Ethical and Transparent Research

Maintaining highest standards of scientific integrity and regulatory compliance.

  • Full compliance with FDA and EMA regulations
  • Transparent clinical trial reporting
  • Independent ethics committee oversight
Regulatory Compliance Ethical Standards Transparency Metrics
100% regulatory adherence International research ethics certifications Public disclosure of clinical trial results
Collaborative Scientific Ecosystem

Strategic partnerships and collaborative research initiatives.

  • Collaborations with 5 major research institutions
  • Joint research programs with academic centers
  • International scientific network engagement
Research Partnerships Collaborative Grants Scientific Conferences
University of Pennsylvania $1.5 million collaborative research funding 6 international conference presentations

DCF model

Enlivex Therapeutics Ltd. (ENLV) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.